查看“PARPi”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>PARPi</strong> 是 <strong>Poly (ADP-ribose) Polymerase Inhibitor</strong>（多聚ADP核糖聚合酶抑制剂）的通用缩写。这类药物是首个成功利用<strong>[[合成致死]]</strong>（Synthetic Lethality）概念获批上市的抗癌靶向药。PARPi 通过抑制 PARP1/2 酶的活性并捕获 PARP 蛋白，阻断 DNA 单链修复，导致携带 <strong>[[BRCA1]]/[[BRCA2]]</strong> 突变或同源重组缺陷（HRD）的肿瘤细胞因 DNA 双链断裂累积而死亡。目前，PARPi 已彻底改变了[[卵巢癌]]的治疗模式（从“等待复发”转变为“主动维持”），并在[[乳腺癌]]、[[前列腺癌]]和[[胰腺癌]]中确立了一线或后线治疗地位。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">PARPi</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">PARP Inhibitors (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    [[Image:PARPi_drug_family_structure.jpg|100px|PARPi家族成员分子结构对比]]
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">类别：DDR 靶向药物</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">全称</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Poly (ADP-ribose) Polymerase inhibitor</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">首个上市</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[奥拉帕利]] (2014)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心机制</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">酶抑制 + [[PARP捕获]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">全球代表</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">Olaparib, Niraparib, Talazoparib, Rucaparib</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">中国代表</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">[[氟唑帕利]], [[帕米帕利]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">关键毒性</th>
                    <td style="padding: 6px 12px; color: #0f172a;">骨髓抑制 (贫血/血小板减少)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">PARPi 家族风云榜</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        虽然所有 PARPi 的作用机制相似，但在药代动力学、捕获能力（Trapping potency）和毒性谱上存在显著差异，临床选药需“因人而异”：
    </p>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 15%;">通用名</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">原研/厂商</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">核心特点</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #b91c1c;">特有毒性</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[奥拉帕利]] (Olaparib)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">阿斯利康</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>标杆药物</strong>。适应症最全，数据最扎实（SOLO-1）。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">恶心、疲乏、轻度贫血</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[尼拉帕利]] (Niraparib)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">GSK / 再鼎</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>穿透力强</strong>。半衰期长（每日一次），在卵巢癌全人群（无论BRCA状态）中获益明确。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>血小板减少</strong> (需根据体重/血小板基线调量)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[塔拉唑帕利]] (Talazoparib)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">辉瑞</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>最强捕获</strong>。药效最强，单药即可对抗乳腺癌。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>重度贫血</strong> (输血依赖)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[卢卡帕利]] (Rucaparib)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">Clovis</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">结构独特，对 BRCA 突变前列腺癌效果好。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>光敏反应</strong> (晒太阳起疹)、转氨酶升高</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[氟唑帕利]] (Fluzoparib)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">恒瑞医药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>中国首个</strong>。双药代优势（半衰期短但组织浓度高），复发性卵巢癌数据优异。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">胃肠道反应</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[帕米帕利]] (Pamiparib)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">百济神州</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>不被P-gp外排</strong>。脑通透性高，适合脑转移患者。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">耐受性较好</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用模式</h2>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>维持治疗 (Maintenance)：</strong> 
            <br>PARPi 最辉煌的战场。卵巢癌患者化疗结束后，若达到缓解（CR/PR），口服 PARPi 可以显著推迟复发。SOLO-1 研究显示奥拉帕利让 BRCA 突变患者多活了数年。</li>
        <li style="margin-bottom: 12px;"><strong>后线治疗 (Late-line)：</strong> 
            <br>用于多线化疗失败的 BRCA 突变乳腺癌、前列腺癌或胰腺癌。此时利用合成致死机制进行“绝地反击”。</li>
        <li style="margin-bottom: 12px;"><strong>联合治疗 (Combination)：</strong> 
            <br><strong>PARPi + 抗血管 (贝伐珠单抗)：</strong> 针对 HRD 阳性卵巢癌，实现“断供+杀伤”双重打击。
            <br><strong>PARPi + 免疫 (PD-1)：</strong> PARPi 造成的 DNA 损伤可激活 cGAS-STING 通路，将冷肿瘤变热，增强免疫疗效。</li>
    </ul>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Lord CJ, Ashworth A. (2017).</strong> <em>PARP inhibitors: Synthetic lethality in the clinic.</em> <strong>[[Science]]</strong>. <br>
            <span style="color: #475569;">[点评]：权威综述，详细回顾了 PARPi 从实验室概念（合成致死）到临床标准治疗的转化历程。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Lafargue CJ, et al. (2021).</strong> <em>Trapping: A Driver of PARP Inhibitor Efficacy and Toxicity?</em> <strong>[[Cancers]]</strong>. <br>
            <span style="color: #475569;">[点评]：深入探讨了不同 PARPi 药物在“捕获能力”上的差异及其对临床疗效和副作用谱的影响，指导精准用药。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Pujade-Lauraine E, et al. (2017).</strong> <em>Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2).</em> <strong>[[The Lancet Oncology]]</strong>. <br>
            <span style="color: #475569;">[点评]：SOLO-2 研究，确立了“片剂”奥拉帕利在复发性卵巢癌维持治疗中的地位，相比旧版胶囊剂型大大减少了服用负担。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            PARPi · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">获批药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[奥拉帕利]] • [[尼拉帕利]] • [[塔拉唑帕利]] • [[氟唑帕利]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心机制</td>
                <td style="padding: 10px 15px; color: #334155;">[[合成致死]] • [[PARP捕获]] • [[DNA损伤修复]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">生物标志物</td>
                <td style="padding: 10px 15px; color: #334155;">[[BRCA1/2]] • [[HRD]] • [[PALB2]] • [[ATM]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">临床应用</td>
                <td style="padding: 10px 15px; color: #334155;">[[维持治疗]] • [[去化疗]] • [[后线挽救]]</td>
            </tr>
        </table>
    </div>

</div>